Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                

Neonatalnutrition: Scott C. Denne

Download as pdf or txt
Download as pdf or txt
You are on page 1of 12

Neonatal Nutrition

Scott C. Denne, MD

KEYWORDS
 Infant nutrition  Breastfeeding  Infant formula  Gastroesophageal reflux

KEY POINTS
 There is good evidence of the clinical benefit of breastfeeding to infants and mothers, and
it should be the primary nutrition source for most infants.
 The breastfed infant is the normative model for infant growth, and the WHO growth curves
should be used for all term infants.
 All standard term infant formulas are clinically equivalent and adequately support growth
for the small proportion of infants who cannot breastfeed.
 Soy and other specialized formulas should be reserved for particular circumstances and
conditions and should not be used routinely.
 Gastroesophageal reflux occurs in most infants and does not require intervention. Gastro-
esophageal reflux disease occurs in a small proportion of infants and an algorithm-based
evaluation and management strategy should be used.

NEONATAL NUTRITION

There is accumulating evidence that nutrition and growth in early life can have
substantial influences on adult health.1 This article reviews the current knowledge,
recommendations, and approaches to feeding the normal newborn. The current un-
derstanding and approach to the common and sometimes difficult problem of gastro-
esophageal reflux (GER) in normal infants is also discussed.

BREASTFEEDING

Based on the many demonstrated benefits for babies and mothers, the World Health
Organization (WHO), the American Academy of Pediatrics (AAP), and Institute of
Medicine recommend the exclusive use of human milk for healthy term infants for
the first 6 months of life, and continued breastfeeding for at least 12 months.2
The public health goal for Healthy People 2020 is for 82% of mothers to initiate breast-
feeding, 60% of mothers to be breastfeeding at 6 months, and 34% to be breastfeed-
ing at 1 year.3 The Centers for Disease Control and Prevention (CDC) tracks these

Disclosure Statement: Nothing to disclose.


Department of Pediatrics, Indiana University, 699 Riley Hospital Dr, RR 208, Indianapolis, IN
46202, USA
E-mail address: sdenne@iu.edu

Pediatr Clin N Am 62 (2015) 427–438


http://dx.doi.org/10.1016/j.pcl.2014.11.006 pediatric.theclinics.com
0031-3955/15/$ – see front matter Ó 2015 Elsevier Inc. All rights reserved.
428 Denne

breastfeeding rates and issues a breastfeeding report card yearly.4 Significant prog-
ress has been made toward achieving these breastfeeding goals, and in 2011 79%
of women initiated breastfeeding. However, additional progress is necessary in the
duration and exclusivity of breastfeeding. The most recent data on breastfeeding rates
and the goals of Healthy People 2020 are shown in Fig. 1.
To support higher breastfeeding rates, additional objectives of Healthy People 2020
include increasing the proportion of employers that have worksite lactation support
programs, reducing the number of breastfed newborns who receive formula supple-
mentation within the first 2 days of life, and increasing the proportion of live births
that occur in facilities that provide recommended care for lactating mothers and their
babies.3
Although there has been progress in overall breastfeeding rates, these gains have
not been uniform across all populations and geographic regions.5 Breastfeeding rates
are lower for black infants, infants of mothers with lower incomes, and mothers with
less education.5–7 Breastfeeding rates are lower in the southern United States and
in rural areas.5,8 Health care workers should be aware of these disparities so that
they can focus their attention on these groups to educate about and support breast-
feeding, and help others overcome barriers to breastfeeding.

Breastfeeding and Clinical Outcomes


There is growing evidence that breastfeeding conveys important benefits during child-
hood and in later adult life, and to breastfeeding mothers.9 However, the evidence
for these benefits comes almost entirely from observational cohort studies and not
randomized clinical trials; randomized controlled trials of breastfeeding are widely

Fig. 1. US breastfeeding rates in 2011 (red bars) and Healthy People 2020 goals (green bars).
BF, breastfed. (Data from National Center for Chronic Disease Prevention and Health Promo-
tion. Breast feeding report card. Atlanta, GA: CDC, 2014. Available at: www.cdc.gov/pdf/
2014breastfeedingreportcard.pdf. Accessed November 3, 2014.)
Neonatal Nutrition 429

considered to be impractical and unethical.2,9 Observational trials of clinical benefit


have not always been consistent and can be subject to bias and contain multiple
confounders. However, careful evaluation of multiple studies evaluating breastfeeding
effects in clinical outcomes has been conducted, and meta-analyses performed.9
Based on these meta-analyses, there is convincing evidence of the beneficial effects
of breastfeeding on a variety of infant and maternal clinical outcomes. A list of those
significant outcomes is provided in Box 1.
Several other benefits associated with breastfeeding have also been reported, but
the evidence has been inconsistent and/or less convincing. This includes associations
between breastfeeding and cognitive development, obesity in later life, cardiovascular
mortality in adulthood, and postpartum depression.9

Composition of Human Milk


Human milk is a complex and dynamic fluid that supports ideal infant growth and im-
mune function development.10 The composition of human milk changes over time, and
contains live cells along with macronutrients and micronutrients and bioactive factors.
Colostrum is the first fluid secreted by the breast following delivery, and has
an intense yellow color because of the high concentration of carotenoids. Colostrum
is produced in low quantities for the first few days, and contains bioactive components
including secretory IgA, lactoferrin, leucocytes, and epidermal growth factor.
Compared with later milk, colostrum contains relatively low concentrations of lactose,
potassium, and calcium and higher levels of sodium chloride and magnesium.10 As
lactose secretion becomes more efficient and milk lactose concentration increases,
the colostrum/milk sodium concentration decreases proportionally.
Transitional milk appears at 5 to 14 days and contains increased amounts of
lactose, fat, and total calories along with lower concentrations of immunoglobulins
and total proteins. At 2 to 4 weeks, human milk is considered mature and the

Box 1
Reduction in disease/condition associated with breastfeeding

Infant
Otitis media
Recurrent otitis media
Respiratory tract infection
Asthma
Atopic dermatitis
Gastroenteritis
Type 1 and 2 diabetes
Leukemia
Sudden infant death syndrome
Mother
Breast cancer
Ovarian cancer

Data from Ip S, Chung M, Raman G, et al. A summary of the Agency for Healthcare Research
and Quality’s evidence report on breastfeeding in developed countries. Breastfeed Med
2009;4 Suppl 1:S17–30.
430 Denne

composition remains stable for the next several months.11 The change in macronu-
trient concentration in human milk over time is shown in Fig. 2.
The macronutrient mineral, vitamin, and micronutrient concentration of mature hu-
man milk is shown in Table 1. It must be pointed out that Table 1 lists average compo-
sition values; there is substantial variability in the nutrient content of human milk
across individual mothers. Furthermore, aliquots of milk from one mother can also
be quite different in composition. However, the mother-infant dyad seems to success-
fully adapt to these variations, and successful breastfeeding and normal infant growth
is achieved for most mothers and infants.
Human milk contains live cells and a large variety of bioactive substances.5,10 Mac-
rophages, T cells, and lymphocytes are all found in human milk, with macrophages be-
ing the predominant cell type. These cells most likely perform an important host
defense function for the infant. Multiple bioactive factors are present in human milk
including immunoglobulins, growth factors, cytokines, and other small molecules. A
partial list of bioactive substances contained in human milk along with their proposed
function is shown in Table 2.

Growth and Growth Standards


The WHO conducted a well-designed, longitudinal study of healthy term breastfed in-
fants accurately measuring growth from birth to 2 years of age.12 Data were obtained
from 903 infants who were exclusively or predominantly breastfed for 4 to 6 months
and who continued breastfeeding for at least 12 months. The study was conducted
in six diverse geographic areas (Brazil, India, Ghana, Norway, Oman, and the United
States). The resulting growth charts contain extensive information including weight
for age, length for age, head circumference for age, and weight for length and body
mass index for age. These WHO growth curves are considered the normative model
for growth and development regardless of infant ethnicity or geography, and reflects
optimal growth of the breastfed infant. The CDC and AAP recommend the use of the

Fig. 2. Change in macronutrient composition of human milk over time. (Data from Gidre-
wicz DA, Fenton TR. A systematic review and meta-analysis of the nutrient content of pre-
term and term breast milk. BMC Pediatr 2014;14(1):216.)
Neonatal Nutrition 431

Table 1
Concentrations of selected nutrients in mature (2 wk) human milk

Energy 66  9 kcal
Protein 1.3  0.2 g
Fat 3.0  0.9 g
Lactose 6.2  0.6 g
Calcium 28  7 mg
Phosphorus 15  4 mg
Sodium 18  4 mg
Potassium 53  4 mg
Chloride 42  6 mg
Iron 0.03  0.01 mg
Vitamin D 2.2  0.4 IU/100 mL

All concentrations per 100 mL; mean  SD.


Data from Kleinman R. Pediatric Nutrition Handbook. 7th edition. Elk Grove Village (IL): Amer-
ican Academy of Pediatrics; 2014; and Gidrewicz DA, Fenton TR. A systematic review and meta-
analysis of the nutrient content of preterm and term breast milk. BMC Pediatr 2014;14(1):216.

WHO growth curves for all children younger than 24 months. These growth charts are
readily available on the CDC Web site (www.cdc.gove/growthcharts/who_charts.htm).

Supplements for Breastfed Infants


Although human milk is uniquely suited to support normal infant growth, human milk
is low in vitamin D and iron, and deficiency can occur. Therefore, the AAP recom-
mends 400 IU/day vitamin D supplementation for all breastfed infants.5 Vitamin D
supplementation should begin in the first few days of life and continue until the infant
is weaned to at least 1 L/day or 1 quart/day of vitamin D–fortified formula or whole
milk. Supplementation of 1 mg/kg/day of oral iron should start at 4 months of age
and continue until the infant consumes adequate oral iron from foods.

Table 2
Selected bioactive compounds in human milk

Compound Proposed Function


Immunoglobulins (IgA, IgM, IgG) Infection prevention
Cytokines Infection prevention, reduce inflammation
Oligosaccharides Promote beneficial flora
Nucleotides Promote beneficial flora
Lactoferrin Intestinal growth, immunomodulation
Epidermal growth factor Intestinal maturation and repair
Insulin-like growth factor 1 and 2 Tissue growth
Erythropoietin Prevention of anemia, intestinal development
Vascular endothelial growth factor Regulation of angiogenesis

Data from Kleinman R. Pediatric nutrition handbook. 7th edition. Elk Grove Village (IL): American
Academy of Pediatrics; 2014; and Ballard O, Morrow AL. Human milk composition: nutrients and
bioactive factors. Pediatr Clin North Am 2013;60(1):49–74.
432 Denne

Duration of Breastfeeding
The AAP, WHO, and Institute of Medicine recommend exclusive breastfeeding for
about 6 months, with continuation after complementary foods have been introduced
for at least the first year of life.2,5 Breastfeeding can be extended beyond the first
year of life as mutually desired by the mother and child. It is important to point out
that the definition of exclusive breastfeeding includes the administration of vitamin
D and iron.

Contraindications to Breastfeeding
There are a limited number of medical circumstances where breastfeeding is contra-
indicated. These include some maternal infections, particular inborn errors of meta-
bolism in infants, and a few maternal medications.
Maternal medical conditions that preclude breastfeeding include human T-cell lym-
photropic virus (type 1 and 2), untreated brucellosis, active pulmonary tuberculosis
without 2 weeks of completed treatment, and active herpes simplex lesions on
the breast.2,5 In the industrialized world, breastfeeding is also contraindicated for
HIV-positive mothers. Because the primary carbohydrate of breast milk is lactose, a
disaccharide composed of glucose and galactose, infants with the inborn error of
metabolism of galactosemia should not be breastfed. Although most maternal medi-
cations are compatible with breastfeeding, certain medications are a contraindication
to breastfeeding, such as mothers receiving antineoplastic drug therapy. Because of
the rapidly changing information on medications relative to breastfeeding, it is advis-
able to consult the drugs and lactation database (LacMed) before making a determi-
nation. LacMed is easily accessible from the US National Library of Medicine Web site
(http://docsnet.nlm.nih.gov).

Supporting Breastfeeding
Providing support to the breastfeeding mother requires appropriate institutional pol-
icies and the knowledge and attention of health care providers. To ensure that breast-
feeding is supported in the hospital, the World Health Organization has provided 10
steps to successful breastfeeding (Box 2). The 10-step program has been effective
in increasing rates of breastfeeding initiation, exclusivity, and duration.13
Following hospital discharge, the primary care physician should see all breastfeed-
ing newborns at 3 to 5 days of age or within 48 to 72 hours after discharge from the
hospital.2 At this visit, the physician should evaluate body weight and establish that
weight loss is no more than 7% from birth, and that there is no further weight loss
by Day 5. If weight loss is of concern, feeding should be assessed and more frequent
follow-up should be scheduled. Infant elimination patterns should be discussed and
hydration evaluated. One feeding should be observed and any other maternal and in-
fant issues discussed.

Common Breastfeeding Problems


Common problems of breastfeeding mothers include nipple pain, engorgement, and
mastitis.14 Nipple pain is common in the first few days of breastfeeding. This can usu-
ally be addressed with good positioning, optimal attachment of the infant at the breast,
and removal from the breast when the infant is satisfied. A lactation expert may be
useful in helping mothers achieve proper attachment and removal.
Breast engorgement and tenderness often occurs at 3 to 5 days. More frequent
breastfeeding and breast massage after feeds are helpful. Mastitis is characterized
by a painful red swollen and hard area of the breast, fever, and malaise; mastitis
Neonatal Nutrition 433

Box 2
World Health Organization ten steps to successful breastfeeding

1. Have a written breastfeeding policy that is routinely communicated to all health care staff.
2. Train all health care staff in the skills necessary to implement this policy.
3. Inform all pregnant women about the benefits and management of breastfeeding.
4. Help mothers initiate breastfeeding within the first hour of birth.
5. Show mothers how to breastfeed and how to maintain lactation even if they are separated
from their infants.
6. Give newborn infants no food or drink other than breast milk, unless medically indicated.
7. Practice rooming-in (allow mothers and infants to remain together) 24 hours a day.
8. Encourage breastfeeding on demand.
9. Give no artificial nipples or pacifiers to breastfeeding infants.a
10. Foster the establishment of breastfeeding support groups and refer mothers to them on
discharge from hospital.
a
The AAP does not support a categorical ban on pacifiers because of their role in sudden in-
fant death syndrome risk reduction and their analgesic benefit during painful procedures.
From World Health Organization. Evidence for the Ten Steps to Successful Breastfeeding.
Geneva, Switzerland, 1998. Available at: www.who.int/nutrition/publications/evidence_ten_
step_eng.pdf. Accessed November 3, 2014.

can occur in 10% to 20% of mothers. Treatment consists of frequent and effective milk
removal and sometimes antibiotics.

FORMULA FEEDING: INDICATIONS

Although breastfeeding is preferred for most normal healthy term infants, formula
feeding can support nutrition and growth. The indications for the use of infant formulas
include (1) as a substitute (or as a supplement) for human milk in infants whose
mothers choose not to breastfeed or not to do so exclusively, (2) as a substitute for
human milk in infants where breastfeeding is medically contraindicated, and (3) as a
supplement for breastfed infants who’s intake of human milk does not support
adequate weight gain.5 It must be noted that the supplementation should be instituted
only after interventions to increase milk supply have been ineffective.
Infant Formulas
Infant formulas are regulated by the Food and Drug Administration and manufacturers
must ensure by analysis the amount of 29 essential nutrients in each batch of for-
mula.15 All commercially available standard term infant formulas in the United States
support normal growth and development of healthy term infants. Although products
from different manufacturers may vary slightly in their nutrient composition, the prod-
ucts are much more similar than different. At present, there is no clinical evidence that
differences in term infant formulas have any important measurable clinical effects, and
there is no medical reason to prefer one brand over another.
Infant formulas are available in ready to feed, in concentrated liquid, and in powder.
Proper preparation of the liquid concentrate and the powder forms is essential, and
detailed instructions are found on each manufacturer’s Web site. Standard infant for-
mula contains 19 or 20 calories per ounce, which is similar to the average caloric con-
tent of breast milk (recognizing the previously discussed variability of human milk).
434 Denne

However, infant formula contains about a 50% higher amount of protein than human
milk (approximately 1.4 g/100 mL protein in infant formula). The amount of fat in infant
formula is similar to human milk (approximately 3.6 g/100 mL); the fat is provided pri-
marily by mixtures of vegetable oils. Most infant formula manufacturers have added
very long chain polyunsaturated fatty acids (arachidonic acid and docosahexaenoic
acid) to their formulas. These compounds may help to promote brain and visual devel-
opment, although the long-term benefit of these additives seems to be minimal or
nonexistent.16 There are, however, no safety concerns by the addition of docosahex-
aenoic acid and arachidonic acid to infant formulas. The carbohydrate concentration
in infant formula (approximately 7.5 g/100 mL) and composition (predominantly
lactose) is similar to human milk.
All standard infant formulas contain iron, ideally at a concentration of 12 mg/L. This
concentration of iron prevents development of iron deficiency and anemia. However,
low-iron infant formulas continue to be available based on a perception of gastrointes-
tinal (GI) symptoms (colic, constipation) with the use of higher-iron formulas. However,
multiple well-controlled studies have consistently failed to demonstrate any difference
in GI symptoms between higher and lower iron-containing formulas. It is the position of
the AAP that there is no role for low-iron formulas in the feeding of healthy term infants.5

Other Nutrients in Infant Formulas


The composition of infant formulas is constantly changing, often with the intent to
become closer in composition to human milk. Many available commercial infant for-
mulas now contain nucleotides and oligosaccharides (prebiotics). Although there
are no concerns about the safety of these additions, there is currently no compelling
clinical evidence demonstrating benefit.
Several infant formulas contain probiotics, nonpathogenic microorganisms that may
promote “healthy” colonic microflora. Although these probiotics seem to be safe for
use in healthy term infants, there is currently insufficient evidence to recommend
routine use of these formulas.5

Soy Formulas
Although the routine use of soy formulas is not recommended, current commercially
available soy formulas adequately support growth and bone mineralization of healthy
term infants.17,18 All soy formulas are lactose free, and can be used to feed infants who
cannot tolerate milk protein or lactose. The specific conditions where soy formula is
recommended and not recommended by the AAP is shown in Box 3.5,19

Infant Formulas with Extensively Hydrolyzed Protein


These specialized infant formulas are expensive and have a bitter taste, and should
not be used for healthy term infants. The extensively hydrolyzed protein formulas
are lactose free and often contain a large amount of medium chain triglycerides,
and can sometimes be useful in selected infants with malabsorption syndromes
(eg, cystic fibrosis, short gut syndrome, biliary atresia, cholestasis, and protracted
diarrhea). These formulas can also be useful for infants who are severely intolerant
to intact cow milk protein. The use of extensively hydrolyzed protein formulas should
be limited to these indications.5

GASTROESOPHAGEAL REFLUX AND GASTROESOPHAGEAL DISEASE

GER occurs in most infants (70%–85% within the first 2 months of life), and is often
seen as a problem by parents and physicians. However, it is clear that GER is part
Neonatal Nutrition 435

Box 3
AAP recommendations for the use of soy formula in term infants

Recommended for the following conditions or situations:


1. Galactosemia or hereditary lactase deficiency
2. Documented transient lactase deficiency
3. Documented IgE-associated allergy to cow milk without allergy to soy protein
4. Desired vegetarian diet
Not recommended for:
1. Preterm infants with birth weights less than 1800 g
2. Prevention treatment of colic
3. Prevention of atopic disease
4. Infants with cow milk protein–induced enteropathy or enterocolitis

Data from Kleinman R. Pediatric nutrition handbook. 7th edition. Elk Grove Village (IL): Amer-
ican Academy of Pediatrics; 2014; and Bhatia J, Greer F. Use of soy protein-based formulas in
infant feeding. Pediatrics 2008;121(5):1062–8.

of normal physiology and occurs multiple times a day in healthy infants, children, and
adults. Most infants have uncomplicated GER (“happy spitters”) and require no more
than parental education and reassurance. However, it is important to identify the small
portion of infants who have gastroesophageal reflux disease (GERD) who require addi-
tional evaluation, monitoring, and sometimes treatment. These issues are briefly dis-
cussed here; a variety of excellent and comprehensive recent reviews of GER and
GERD are available.19–24

Symptoms of Gastroesophageal Reflux Disease


Distinguishing between GER and GERD can be difficult in infants. Symptoms associ-
ated with GERD include feeding refusal, poor weight gain, irritability, dysphasia, arch-
ing of the back during feedings, sleep disturbance, and respiratory symptoms.
However, no single symptom or group of symptoms can reliably diagnose GERD in in-
fants, or predict which infants will respond to therapy.23 However, there is a validated
questionnaire for documenting and monitoring of parent report of GERD symptoms in
infants that may be useful to clinicians.25

Evaluation and Management of Gastroesophageal Reflux/Gastroesophageal Reflux


Disease
Evaluation of GER/GERD in infants primarily consists of a comprehensive history
and physical examination. In addition to eliciting a history of GERD-associated
symptoms, it is important to ensure the absence of other concerning symptoms:
bilious vomiting, GI bleeding, forceful vomiting, abdominal tenderness or distention,
bulging fontanel, macrocephaly and microcephaly, and seizures.20,23 The presence
of any of these symptoms should prompt additional evaluation based on the partic-
ular symptom. With a normal physical examination, appropriate weight gain, and the
absence of GERD-associated and other concerning symptoms, no additional diag-
nostic evaluation is necessary. Education and reassurance should be provided to
the parents. In some cases, thickened feedings could be considered. If thickened
feedings are to be used, they can be provided by adding up to 1 tablespoon of
436 Denne

dry rice cereal to 1 ounce of formula or by using a commercially thickened full term
infant formula.23 Thickened feedings are likely to have little effect on the actual num-
ber of reflux episodes but rather reduce the number of observed regurgitations.
There is no information on the long-term effects of thickened infant feedings. There
is a possible association between thickened feedings and necrotizing entercolitis in
preterm infants, and therefore commercial thickened infant formula should not be
used in infants born before 37 weeks gestation who have been discharged from
the hospital in the past 30 days.

VomiƟng/regurgitaƟon with poor weight gain

History and physical exam

Yes
Concerning symptoms present? Evaluate
(Bilious vomiƟng, GI bleeding, etc) further

No
Yes
Adequate caloric intake? EducaƟon, Close follow up

No

CBC,U/A, electrolytes, creaƟnine, urea, celiac screen (> 6mos)


Consider: Upper GI series

Yes
Abnormal? Manage accordingly

No

Dietary management:
Maternal exclusion diet if breasƞed; Protein hydrolysate if formula fed
Thickened feedings; Increased caloric density

Yes
Improved? EducaƟon, Close follow up

No

ConsultaƟon with Pediatric GI


Consider: acid suppression therapy and/or prokineƟcs
Consider: Observe parent child interacƟon
Consider: NG or NJ feeds

Fig. 3. Algorithm for the evaluation and management of infants with vomiting/regurgita-
tion and poor weight gain as developed by the North American Society for Pediatric
Gastroenterology, Hepatology, and Nutrition and endorsed by the AAP. CBC, complete
blood count; GI, gastrointestinal; NG, nasogastric; NJ, nasojejunal; U/A, urinalysis. (Adapted
from Vandenplas Y, Rudolph CD, Di Lorenzo C, et al. Pediatric gastroesophageal reflux clin-
ical practice guidelines: joint recommendations of the North American Society for Pediatric
Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for
Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol
Nutr 2009;49(4):498–547, with permission; and Lightdale JR, Gremse DA. Gastroesophageal
reflux: management guidance for the pediatrician. Pediatrics 2013;131(5):
e1684–95.)
Neonatal Nutrition 437

Although most infants with GER need only routine evaluation and minimal if
any intervention, infants with poor weight gain along with regurgitation and/or vomiting
require additional evaluation and possible treatment. An approach to the infant with
recurrent regurgitation and poor weight gain, as proposed by the North American So-
ciety for Gastroenterology, Hepatology and Nutrition, is shown in Fig. 3.20 After
ensuring that there are no significant concerning other symptoms and caloric intake
is adequate, evaluation consists of some screening blood work along with possibly
an upper GI tract series. An upper GI series is useful for evaluating a possible malro-
tation or duodenal web. If there is persistent or forced vomiting in the first few months
of life, pyloric ultrasonography should be performed to evaluate for pyloric stenosis. If
these screening tests are normal, a trial of dietary management can be initiated. For
breastfeeding mothers, a 2- to 4-week trial of a diet that restricts milk and egg is rec-
ommended; this is to address a potential milk protein allergy. For formula-fed infants,
some extensively hydrolyzed protein formula may be appropriate. In addition, thick-
ened feedings may also be useful.
If these interventions result in clinical improvement, they should be continued with
additional close follow-up. If there is no improvement, consultation with a pediatric
gastroenterologist should be strongly considered. Some consideration may be given
to acid-suppression therapy. Although treatment with a prokinetic (eg, metoclopra-
mide) may be considered, the risks of this therapy may outweigh the benefits.26
Indeed, metoclopramide carries a Food and Drug Administration black box warning
regarding its adverse effects. In general, use of pharmacologic therapy for infants
with GERD should be uncommon and likely requires comanagement with a pediatric
gastroenterologist.

REFERENCES

1. Robinson S, Fall C. Infant nutrition and later health: a review of current evidence.
Nutrients 2012;4(8):859–74.
2. Breastfeeding and the use of human milk. Pediatrics 2012;129(3):e827–41.
3. Healthy People 2020. Gov. Available at: http://www.healthypeople.gov/2020/
topics. Accessed November 3, 2014.
4. Centers for Disease Control and Prevention. Breastfeeding Report Card, United
States, 2014. Available at: www.cdc.gov/pdf/2014breastfeedingreportcard.pdf.
Accessed November 3, 2014.
5. Kleinman R. Pediatric nutrition handbook. 7th edition. Elk Grove Village (IL):
American Academy of Pediatrics; 2014.
6. Fein SB, Labiner-Wolfe J, Shealy KR, et al. Infant feeding practices study II: study
methods. Pediatrics 2008;122(Suppl 2):S28–35.
7. Ryan AS, Wenjun Z, Acosta A. Breastfeeding continues to increase into the new
millennium. Pediatrics 2002;110(6):1103–9.
8. U.S. Department of Health and Human Services. The Surgeon General’s Call to
Action to Support Breastfeeding. Washington (DC): U.S. Department of Health
and Human Services, Office of the Surgeon General; 2011.
9. Ip S, Chung M, Raman G, et al. A summary of the Agency for Healthcare
Research and Quality’s evidence report on breastfeeding in developed countries.
Breastfeed Med 2009;4(Suppl 1):S17–30.
10. Ballard O, Morrow AL. Human milk composition: nutrients and bioactive factors.
Pediatr Clin North Am 2013;60(1):49–74.
11. Gidrewicz DA, Fenton TR. A systematic review and meta-analysis of the nutrient
content of preterm and term breast milk. BMC Pediatr 2014;14(1):216.
438 Denne

12. de Onis M, Garza C, Onyango AW, et al. Comparison of the WHO child growth
standards and the CDC 2000 growth charts. J Nutr 2007;137(1):144–8.
13. World Health Organization. Evidence for the Ten Steps to Successful Breastfeed-
ing. Geneva, Switzerland, 1998. Available at: www.who.int/nutrition/publications/
evidence_ten_step_eng.pdf. Accessed November 3, 2014.
14. Bergmann RL, Bergmann KE, von Weizsacker K, et al. Breastfeeding is natural
but not always easy: intervention for common medical problems of breastfeeding
mothers. A review of the scientific evidence. J Perinat Med 2014;42(1):9–18.
15. Drugs Fa. 21 CFR 107. 2009. Available at: http://www.gpo.gov/fdsys/pkg/CFR-
2009-title21-vol1/content-detail.html. Accessed November 3, 2014.
16. Simmer K, Patole SK, Rao SC. Long-chain polyunsaturated fatty acid supplemen-
tation in infants born at term. Cochrane Database Syst Rev 2011;(12):CD000376.
17. Lasekan JB, Ostrom KM, Jacobs JR, et al. Growth of newborn, term infants fed
soy formulas for 1 year. Clin Pediatr 1999;38(10):563–71.
18. Venkataraman PS, Luhar H, Neylan MJ. Bone mineral metabolism in full-term in-
fants fed human milk, cow milk-based, and soy-based formulas. Am J Dis Child
1992;146(11):1302–5.
19. Bhatia J, Greer F. Use of soy protein-based formulas in infant feeding. Pediatrics
2008;121(5):1062–8.
20. Vandenplas Y, Rudolph CD, Di Lorenzo C, et al. Pediatric gastroesophageal re-
flux clinical practice guidelines: joint recommendations of the North American So-
ciety for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and
the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition
(ESPGHAN). J Pediatr Gastroenterol Nutr 2009;49(4):498–547.
21. Forbes D. Mewling and puking: infantile gastroesophageal reflux in the 21st cen-
tury. J Paediatr Child Health 2013;49(4):259–63.
22. Czinn SJ, Blanchard S. Gastroesophageal reflux disease in neonates and infants:
when and how to treat. Paediatr Drugs 2013;15(1):19–27.
23. Lightdale JR, Gremse DA. Gastroesophageal reflux: management guidance for
the pediatrician. Pediatrics 2013;131(5):e1684–95.
24. Rosen R. Gastroesophageal reflux in infants: more than just a phenomenon.
JAMA Pediatr 2014;168(1):83–9.
25. Kleinman L, Revicki DA, Flood E. Validation issues in questionnaires for diagnosis
and monitoring of gastroesophageal reflux disease in children. Curr Gastroen-
terol Rep 2006;8(3):230–6.
26. Craig WR, Hanlon-Dearman A, Sinclair C, et al. Metoclopramide, thickened feed-
ings, and positioning for gastro-oesophageal reflux in children under two years.
Cochrane Database Syst Rev 2004;(4):CD003502.

You might also like